James Warren Huff - Net Worth and Insider Trading

James Warren Huff Net Worth

The estimated net worth of James Warren Huff is at least $5 Million dollars as of 2024-03-28. James Warren Huff is the CEO of Reata Pharmaceuticals Inc and owns about 28,166 shares of Reata Pharmaceuticals Inc (RETA) stock worth over $5 Million. Details can be seen in James Warren Huff's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that James Warren Huff has not made any transactions after 2020-11-10 and currently still holds the listed stock(s).

Transaction Summary of James Warren Huff

To

James Warren Huff Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, James Warren Huff owns 1 companies in total, including Reata Pharmaceuticals Inc () .

Click here to see the complete history of James Warren Huff’s form 4 insider trades.

Insider Ownership Summary of James Warren Huff

Ticker Comapny Transaction Date Type of Owner
Reata Pharmaceuticals Inc 2020-11-10 director & See Remarks

James Warren Huff Latest Holdings Summary

James Warren Huff currently owns a total of 1 stock. James Warren Huff owns 28,166 shares of Reata Pharmaceuticals Inc (RETA) as of November 10, 2020, with a value of $5 Million.

Latest Holdings of James Warren Huff

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
RETA Reata Pharmaceuticals Inc 2020-11-10 28,166 172.36 4,854,692

Holding Weightings of James Warren Huff


James Warren Huff Form 4 Trading Tracker

According to the SEC Form 4 filings, James Warren Huff has made a total of 2 transactions in Reata Pharmaceuticals Inc (RETA) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Reata Pharmaceuticals Inc is the sale of 81,657 shares on November 10, 2020, which brought James Warren Huff around $14 Million.

Insider Trading History of James Warren Huff

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

James Warren Huff Trading Performance

GuruFocus tracks the stock performance after each of James Warren Huff's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by James Warren Huff is 32.73%. GuruFocus also compares James Warren Huff's trading performance to market benchmark return within the same time period. The performance of stocks bought by James Warren Huff within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how James Warren Huff's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of James Warren Huff

Average Relative Return

104.9%

Average relative return per transaction

Outperforming Transactions

100%

1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Relative Return(%) 39.79 32.73 75.45 104.9 57.63 81.44
Relative Return to S&P 500(%) 39.62 29.32 71.08 89.15 43.5 71.99

James Warren Huff Ownership Network

Ownership Network List of James Warren Huff

No Data

Ownership Network Relation of James Warren Huff


James Warren Huff Owned Company Details

What does Reata Pharmaceuticals Inc do?

Who are the key executives at Reata Pharmaceuticals Inc?

James Warren Huff is the director & See Remarks of Reata Pharmaceuticals Inc. Other key executives at Reata Pharmaceuticals Inc include director & 10 percent owner Antal Rohit Desai , SVP & Chief Accounting Officer Bhaskar Anand , and EVP & Chief R&D Officer Rajiv Patni .

Reata Pharmaceuticals Inc () Insider Trades Summary

Over the past 18 months, James Warren Huff made no insider transaction in Reata Pharmaceuticals Inc (). Other recent insider transactions involving Reata Pharmaceuticals Inc () include a net sale of 185,892 shares made by Manmeet Singh Soni , a net sale of 150,995 shares made by Dawn Carter Bir , and a net sale of 2,880 shares made by Bhaskar Anand .

In summary, during the past 3 months, insiders sold 0 shares of Reata Pharmaceuticals Inc () in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 530,967 shares of Reata Pharmaceuticals Inc () were sold and 0 shares were bought by its insiders, resulting in a net sale of 530,967 shares.

Reata Pharmaceuticals Inc ()'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Reata Pharmaceuticals Inc Insider Transactions

No Available Data

James Warren Huff Mailing Address

Above is the net worth, insider trading, and ownership report for James Warren Huff. You might contact James Warren Huff via mailing address: C/o Reata Pharmaceuticals, Inc., 2801 Gateway Dr. Suite 150, Irving Tx 75063.

Discussions on James Warren Huff

No discussions yet.